UPDATE -- Aspira Women’s Health Inc. Announces Coverage for OVA1® in the AIM Specialty Health Laboratory Medicine Clinical Guidelines

Rhea-AI Summary

Aspira Women’s Health Inc. (Nasdaq: AWH) announced that its OVA1® ovarian cancer risk assessment test is now recognized as medically necessary by AIM Specialty Health. This new guideline facilitates the preoperative evaluation of pelvic masses, enhancing surgical decisions and patient care. With recent endorsements including New York State Medicaid, the accessibility of OVA1® has significantly increased, particularly among Black women. Aspira aims to address ethnic disparities in ovarian cancer risk assessment, highlighting its commitment to improving women's health outcomes.

Positive

• OVA1® test recognized as medically necessary by AIM Specialty Health, expanding its usage.
• Increased access to OVA1® following positive coverage additions, especially among Black women.
• AIM's endorsement potentially increases demand and utilization of OVA1®.

Negative

• None.

• AIM is a member of the Anthem Blue Cross Blue Shield family of companies which promotes optimal care through use of evidence-based clinical guidelines and real-time decision support for both providers and their patients.
  
  
• AIM is a wholly owned subsidiary of Anthem, Inc., serving more than 50 million members across 50 states, D.C. and US territories.
  

AUSTIN, Texas, July 08, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (Nasdaq: AWH) today announced its OVA1^® risk assessment test for ovarian cancer in women with pelvic masses is considered medically necessary according to AIM Specialty Health’s Clinical Appropriateness Guidelines. AIM Specialty Health is a member of the Anthem Blue Cross Blue Shield family of companies and serves as a specialty benefits management company working with many of the nation’s largest health care organizations. AIM’s mission is to promote appropriate, safe, and affordable health care. As one of the nation’s leading specialty benefits management firms, AIM helps improve the quality of care and reduces the cost for many of the most complex tests and treatments.

The OVA1^® test is now included in AIM’s guidelines for the preoperative evaluation of an adnexal mass when it is indeterminate based on clinical and complete pelvic ultrasound evaluation. The guidelines also include OVA1^® for the determination of the required surgical approach, operator expertise and level of care for an adnexal mass.

Recent positive coverage additions for OVA1^®, such as New York State Medicaid, coupled with peer-reviewed publications documenting OVA1’s superior clinical performance as compared to CA125, especially among Black women, has resulted in a dramatic increase in the number of women who have access to the OVA1^® technology. Aspira Labs, Inc., a subsidiary of Aspira Women’s Health, is the only U.S. provider for Aspira’s proprietary OVA1^® test, an FDA-cleared, ACOG recommended, and Medicare covered ovarian cancer risk assessment tool for women with a pelvic mass.

“We are excited to provide access to OVA1plus™, to such a large segment of the population,” said Valerie Palmieri, President and CEO of Aspira Women’s Health Inc. “This guideline from an organization with a robust technology assessment process expands our ability to truly change the standard of care and helps advance our commitment to making OVA1^® accessible to ALL women.”

About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. (formerly known as Vermillion, Inc., Nasdaq: VRML) is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. Aspira Women’s Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1plus™ combines our FDA-cleared products, OVA1^® and OVERA^®, to detect risk of ovarian malignancy in women with adnexal masses. Aspira GenetiX™ testing offers both targeted and more comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Women’s Health is delivering a portfolio of pelvic mass products over a patient’s lifetime with our cutting-edge research. The next generation of products in development are OVASight™ and EndoCheck™. Visit our website for more information at www.aspirawh.com.

Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Tel 617-430-7577
Arr@lifesciadvisors.com

FAQ

What is the significance of AIM recognizing OVA1® for Aspira Women’s Health (AWH)?

AIM's recognition indicates that the OVA1® test is considered medically necessary, which may enhance its adoption in clinical settings.

How does the AIM guideline impact the OVA1® test availability for patients?

The AIM guideline increases the accessibility of the OVA1® test, particularly for women with indeterminate pelvic masses.

What population benefits from the OVA1® test according to the press release?

The press release highlights improved access to the OVA1® test for Black women, addressing ethnic disparities in ovarian cancer risk assessment.

What has contributed to the increased demand for the OVA1® test?

Recent endorsements, such as coverage from New York State Medicaid, have significantly boosted demand for the OVA1® test.

What financial implications does the AIM guideline have for Aspira Women’s Health (AWH)?

The endorsement by AIM could lead to increased usage and revenue for Aspira, positively impacting its financial performance.